Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11968322 | 0.78 | ALDH1A1 (0.35) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL4492627 | 0.78 | ALDH1A1 (0.35) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL4481346 | 0.78 | ALDH1A1 (0.33) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL4493017 | 0.78 | ALDH1A1 (0.33) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL11968287 | 0.78 | ALDH1A1 (0.33) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL2326613 | 0.74 | ALDH1A1 (0.36) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL4495190 | 0.70 | — | — | |
| SCHEMBL1549418 | 0.65 | — | — | |
| SCHEMBL4503981 | 0.65 | LMNA (0.32) | LMNASMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL4480399 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044034-B1 | ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1(11B-HSD 1) | HOFFMANN LA ROCHE (CH) | 2012-08-22 | — | — | EP | claimed |
| US-20080009499-A1 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | claimed |
| EP-2044034-B1 | ALKYL-PYRIDAZINE DERIVATIVES AS INHIBITORS OF 11 BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1(11B-HSD 1) | HOFFMANN LA ROCHE (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7547697-B2 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080009499-A1 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009499-A1 | Alkyl-pyridazine derivatives as 11b-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | LMNA 1965/4885SMN1; SMN2 2574/4885ALDH1A1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.